Navigation Links
Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
Date:10/27/2008

SUNNYVALE, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today noted an announcement from Birmingham Children's Hospital highlighting results using Cepheid's Xpert(TM) MRSA test, which runs on the GeneXpert(R) System, to implement a screening program for all patients being admitted to its Intensive Care Unit (ICU).

The Birmingham Children's Hospital announcement, released yesterday, stated that "obtaining an accurate and rapid result for MRSA is absolutely key at the emergency admission point in hospitals. For example, if a patient is critically ill and needs to be admitted to the ICU without delay, clinicians simply cannot afford to wait two to three days for a culture result to see whether the patient has MRSA."

"It made sense to start the screening with ICU patients as they are the most susceptible to contracting the MRSA infection due to the bacteria most commonly gaining access to the body through open wounds, injections, catheters and IV sites," said Dr. Jim Gray, Consultant Microbiologist at Birmingham Children's Hospital. "It is vital to prevent MRSA from entering the ICU as it is extremely serious and potentially fatal for children who are already critically ill."

According to the announcement, Cepheid's Xpert(TM) MRSA test has proven to be 100 percent accurate, allowing doctors at the hospital to identify MRSA carriers in under an hour. To validate the 100 percent accuracy rate of the on-demand results obtained using Xpert MRSA, all results so far have been verified with a traditional culture-based test, which takes up to three days for results. The hospital has already identified cases of MRSA that they would normally not have discovered prior to patient admission.

"This is another excellent example demonstrating the growing recognition of rapid molecular-based testing as the basis for best practice surveillance programs," said Rob Koska, Cepheid's Senior Vice President of Worldwide Commercial Operations. "As the leader in Healthcare Associated Infection (HAI) testing, Cepheid is committed to helping institutions worldwide implement the most effective programs that deliver proven results."

About the GeneXpert(R) System Molecular Diagnostic Platform

The GeneXpert(R) System is a closed, self-contained, fully-integrated and automated platform that represents a paradigm shift in the automation of molecular analysis, producing accurate results in a timely manner with minimal risk of contamination. The GeneXpert System is the only system to combine on-board sample preparation with real-time PCR (polymerase chain reaction) amplification and detection functions for fully integrated and automated nucleic acid analysis. The system is designed to purify, concentrate, detect and identify targeted nucleic acid sequences thereby delivering answers directly from unprocessed samples. Modular in design, the GeneXpert System has a variety of configurations to meet the broad range of testing demands of any clinical environment.

About Cepheid

Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.

This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to product performance and future market growth. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: unforeseen manufacturing problems; regulatory developments and changing practices; the failure of products to perform as expected, whether due to manufacturing errors, defects or otherwise; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2007 and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

CONTACTS:

For Media Inquiries:

Jared Tipton

Cepheid Corporate Communications

408-400-8377

jared.tipton@cepheid.com

For Cepheid Investor Inquiries:

Jacquie Ross

Cepheid Investor Relations

408-400-8329

jacquie.ross@cepheid.com


'/>"/>
SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA
2. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
3. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
4. China Medical Technologies Announces Reporting Dates for the September Quarter Results and Addresses Investor Inquiries
5. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
6. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
7. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
8. Orchid Cellmark to Announce Third Quarter 2008 Financial Results on October 30, 2008
9. Caliper Life Sciences Third Quarter 2008 Financial Results Conference Call Notice
10. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
11. Aware, Inc. Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- On Thursday, March 23, 2017, the ... 0.07%; the Dow Jones Industrial Average edged 0.02% lower, ... at 2,345.96, marginally dropping 0.11%. US markets saw a ... sectors finished in red, and 1 sector ended flat ... coverage on the following Biotechnology equities: BioDelivery Sciences International ...
(Date:3/23/2017)... Research and Markets has announced the addition of ... offering. ... The Global Market for Bioproducts Should Reach $714.6 Billion ... of 8.9%, This research report quantifies the ... product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), biocomposite ...
(Date:3/23/2017)... ... 23, 2017 , ... Ellen Matloff, president and CEO of ... as a 2017 Women of Innovation® finalist. Matloff will be among several women ... The dinner recognizes women accomplished in science, technology, engineering and math (STEM), along ...
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
Breaking Biology Technology:
(Date:3/22/2017)... 21, 2017 Vigilant Solutions , a ... enforcement agencies, announced today the appointment of retired FBI ... public safety business development. Mr. Sheridan brings ... including a focus on the aviation transportation sector, to ... position, Mr. Sheridan served as the Aviation Liaison Agent ...
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
Breaking Biology News(10 mins):